News

Varisolve solves varices in veins
Enlarge image

Clinical TrialsUK

Varisolve solves varices in veins

20.11.2012 - British BTG has reported positive results of pivotal Phase III trials. Its drug Varisolve improved the symptoms of varicose veins in 80% of the cases.

PEM (Polidocanol endovenous microfoam) works in varicose veins, veins that have become enlarged and tortuous. BTG International Ltd., London (UK) announced on 19 November that full data from the two US pivotal Phase III trials VANISH-1 and VANISH-2 support previous positive results on PEM. PEM causes fibrosis inside varicose veins, occluding the lumen of the vessel, and reducing the appearance of the varicosity. BTG sells the compound under the brand name Varisolve. VANISH-2 data, presented at the 26th Annual Congress of the American College of Phlebology in Hollywood, Florida (USA) show that 80% of patients treated with PEM 0.5% or 1.0% dose concentrations, reported an improvement of symptoms compared to 20% in the placebo arm. In addition, 85% of patients demonstrated elimination of saphenofemoral junction reflux and/or occlusion of the great saphenous vein (GSV) and all incompetent veins, compared with 2% in the placebo arm.

Patients varied from young (21) to old (73) and baseline GSV diameters from intermediate (3 mm) to wide (19 mm). Side effects were mostly mild or moderate. Out of 230 PEM-treated patients, 24 experienced thrombi. However, all were small and most (77%) were asymptomatic, and – most importantly – all resolved or stabilised in a median time of 29 days. Also, VANISH-1 results support the efficacy of the polyethylen glycol compound. Here PEM treatment led to an improvement of the appearance of varicose veins as assessed by scrutinising photos of them before and after ultrasound-guided delivery of PEM into the incompetent vein.

© eurobiotechnews.eu/ml

http://www.european-biotechnology-news.com/news/news/2012-04/varisolve-solves-varices-in-veins.html

LicensingSwitzerland

30.08.2016 Swiss biopharma company Ferring has acquired the exclusive development and commercialisation rights to Seikagaku’s Phase III chemonucleolytic leg pain treatment for €85m.

Clinical TrialsFrance

26.08.2016 Adocia said it would discontinue its diabetic foot ulcer programme after its lead product BioChaperone PDGF disappointed in Phase III. The French company will turn the focus on its earlier-stage products.

M&AUKSweden

24.08.2016 Pharma major Pfizer is putting the cherry on top of its multi-billion-dollar takeover of Medivation with the acquisition of AstraZeneca’s antibiotics for a cool US$1.5bn. With the divestment, AZ aims to further sharpen its focus.

FinancingUK

23.08.2016 Cambridge University-allied investor Cambridge Innovation Capital has raised £75m (€87m) to reinvest in technology and healthcare companies. Among the backers were Woodford Investment and Winton Ventures.

R&DDenmark

19.08.2016 Together with partner Johnson & Johnson, Danish biotech Genmab is now one step closer to FDA approval with its combination treatment for multiple myeloma after its submission of a supplemental Biologics License Application. In July, Genmab was granted a Breakthrough Therapy Designation (BTD) for its blood cancer therapy.

ResearchUKEU

17.08.2016 Philip Hammond, the UK’S chancellor has announced the government will guarantee funding for EU-backed "structural and investment fund" projects whose timelines extend beyond the UK’s departure from the EU, provided the projects are signed prior to this year's Autumn Statement on the UK budget. The decision ensures continued funding for farmers, companies and institutions involved in the EU’s Horizon 2020 project. The move could cost the UK government up to £6bn (€6.9bn).

Stock marketsGermany

15.08.2016 Back in April, the American FDA gave the green light for the colorectal cancer-screening test Epi procolon. Now Berlin-based diagnostics specialist Epigenomics is considering a secondary listing in the US. A draft of the required registration document was confidentially submitted to the US Securities and Exchange Commission (SEC).

LicensingDenmark

11.08.2016 Danish Genmab AS has granted Gilead Sciences license to use its DuoBody technology platform to develop bispecific antibodies for the treatment of HIV. The deal is worth up to €252m.

Clinical developmentHungaryIreland

09.08.2016 Hungarian Gedeon Richter and Irish Allergan are staying on course in the face of dissappointing Phase III results for depression drug cariprazine. The partners will now begin another Phase III study needed for approval.

ImmunotherapySpain

08.08.2016 Araclon Biotech’s Alzheimer’s vaccine ABvac40 is going forward into Phase II after showing a good safety profile in Phase I. The promising trial results were presented at the Alzheimer’s Association International Conference.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • ARGEN-X (B)14.20 EUR5.19%
  • MAGFORCE (D)4.71 EUR4.43%
  • DIAMYD MEDICAL -B- (S)7.20 SEK4.35%

FLOP

  • BIONOR PHARMA (N)0.41 NOK-6.82%
  • PHOTOCURE (N)41.00 NOK-6.61%
  • SAREUM HOLDINGS (UK)0.74 GBP-5.13%

TOP

  • NORDIC NANOVECTOR (N)34.50 NOK40.8%
  • KARO BIO (S)43.10 SEK30.6%
  • MOLMED (I)0.42 EUR27.3%

FLOP

  • BIONOR PHARMA (N)0.41 NOK-28.1%
  • GW PHARMACEUTICALS (UK)514.61 GBP-13.6%
  • WILEX (D)1.46 EUR-13.6%

TOP

  • NICOX (F)10.29 EUR441.6%
  • SAREUM HOLDINGS (UK)0.74 GBP236.4%
  • GENMAB (DK)1085.00 DKK83.4%

FLOP

  • BB BIOTECH (D)44.30 EUR-83.1%
  • EVOCUTIS (UK)0.04 GBP-77.8%
  • NEUROVIVE PHARMACEUTICAL AB (S)5.65 SEK-75.4%

No liability assumed, Date: 29.08.2016